A retrospective study of prevalence and pattern of international consensus on ANA patterns among patients with hepatitis C virus infection

Shun-Wen Hsiao¹⁺, Chuan-San Fan¹⁺, Hsu-Heng Yen¹⁺³⁴, Siou-Ping Huang¹, Yang-Yuan Chen¹⁺⁵⁺⁶ and Pei-Yuan Su¹

¹ Division of Gastroenterology, Changhua Christian Hospital, Changhua, Taiwan
² General Education Center, Chienkuo Technology University, Changhua, Taiwan
³ Department of Electrical Engineering, Chung Yuan Christian University, Taoyuan, Taiwan
⁴ College of Medicine, National Chung Hsing University, Taichung, Taiwan
⁵ Division of Gastroenterology, Yuanlin Christian Hospital, Changhua, Taiwan
⁶ Department of Hospitality Management, MingDao University, Changhua, Taiwan
⁺ These authors contributed equally to this work.

ABSTRACT

Background. A previous study reported a 30% prevalence of various autoantibodies among patients with hepatitis C virus (HCV) infection. The International Consensus on Anti-Nuclear Antibody (ANA) Patterns was recently introduced to classify ANA patterns based on immunoassay on HEP-2 cells. There is no previous report with this newly developed classification to evaluate patients with HCV infection. The study aims to study the prevalence and pattern of ANA patterns among HCV-infected patients.

Methods. We retrospectively analyzed the medical records of patients with HCV infection from September 2020 to June 2021 at our institution. A positive ANA is defined as a titer of more than 1:320. We compared patient features among the positive and negative groups.

Results. Overall, 258 patients were enrolled—184 patients with negative ANA and 74 patients (28.7%) with positive ANA. The mean age was 67.3 in ANA positive group and 61.2 ANA negative group. Female was prominent with ANA positive and accounted for 63.5%. The most detected ANA pattern was AC-1(homogeneous) (25.9%), followed by AC-4(fine speckled) (25.2%) and AC-21(anti-mitochondrial antibody) (9.6%). In ANA positive group, we found a trend of lower HCV viral load (5.72 log₁₀ IU/ML vs. 6.02 log₁₀ IU/ML), lower alanine aminotransferase level (39.5 U/L vs. 44 U/L), and higher advanced fibrosis (F3 and F4) (38.5% vs. 26.1%). In addition, higher positive ANA (more than 1:640) is significantly associated with lower estimated glomerular filtration rate (eGFR) (77.76 vs. 87.94 mL/min/1.73 m², P = 0.044).

Conclusions. A high prevalence (28.7%) of ANA was found in patients with chronic hepatitis C. The presence of positive ANA is not related to the severity of their hepatic manifestation. However, higher positive ANA was significantly associated with lower eGFR.

Subjects Virology, Epidemiology, Gastroenterology and Hepatology, Infectious Diseases, Internal Medicine
Keywords Hepatitis C virus (HCV), Anti-nuclear antibodies (ANA), ANA pattern

How to cite this article Hsiao S-W, Fan C-S, Yen H-H, Huang S-P, Chen Y-Y, Su P-Y. 2022. A retrospective study of prevalence and pattern of international consensus on ANA patterns among patients with hepatitis C virus infection. PeerJ 10:e14200

https://doi.org/10.7717/peerj.14200
INTRODUCTION

Chronic hepatitis C (CHC) is one of the significant causes of cirrhosis and hepatocellular carcinoma (HCC) worldwide. It is estimated that 74% of patients with CHC had at least one extrahepatic clinical manifestation, such as lymphoma, cryoglobulinemia, glomerulonephritis, arthritis, autoimmune thyroiditis, type 2 diabetes mellitus, and Sjögren’s syndrome (SjS) (Giuggioli et al., 2017; Cacoub & Saadoun, 2021; Negro et al., 2015; Su et al., 2014; Vergani & Mieli-Vergani, 2013). Researchers have found other autoantibodies in patients with CHC, including anti-antinuclear antibody (ANA), anti-smooth muscle antibody (ASMA), anti-mitochondrial antibody (AMA), and anti-liver/kidney microsomes type 1 (anti-LKM1). The prevalence of these autoantibodies was approximately 30% in patients with CHC (Cassani et al., 1997). ANA, detected by indirect immunofluorescence assay of HEp-2 cells (IIFA Hep-2), offers the titer of the fluorescence intensity and provides fluorescence patterns, which are helpful in diagnosing several systemic autoimmune diseases.

Two workshops are used for the standardization and classification of ANA patterns, namely, the International Autoantibody Standardization (IAS) and the International Consensus on ANA Patterns (ICAP) (Agmon-Levin et al., 2014; Damoiseaux et al., 2015). The IAS perspective promotes the standardization and improvement of autoantibodies in laboratory diagnosis. The ICAP classification presents four categories—negative, nuclear, cytoplasmic, and mitotic—and the 29 IIFA Hep-2 patterns with the clinical correlation (Chan et al., 2022; Damoiseaux et al., 2019). Each pattern is assigned a code below the descriptor, namely, anti-cell pattern 1 (AC-1) (Chan et al., 2015).

One decade ago, we used interferon (IFN)-based therapy to treat patients with hepatitis C virus (HCV) infection. Several researchers have reported that IFN-based therapies triggered the development of autoimmune diseases, extrahepatic manifestations, and autoantibodies (Covini et al., 2012; Jadali, 2013; Kajiyama et al., 2012; Marazuela et al., 1996; Novembrino et al., 2014). With the development of direct-acting antiviral agents (DAAs), the treatment of HCV infection has become feasible because DAAs showed a sustained virologic response rate >90%, less intolerance side effects, and short treatment duration compared with IFN-based therapies (Chi et al., 2021; Yen et al., 2020). Several case reports have shown a flare of autoimmune hepatitis or primary biliary cholangitis during or after DAA treatment (Choi et al., 2020; Fianchi, Ponziani & Pompili, 2020; Matsumoto et al., 2018; Montón, Escudero & Pascual, 2020; Nguyen et al., 2018). It is unknown whether the patient or the effect of DAAs triggers the autoimmunity. It is also important to know the autoimmunity status before treatment.

This study was designed to analyze the prevalence of ANA patterns in patients with CHC before DAA treatment and determine the association between different ANA patterns and patient characteristics.
MATERIALS & METHODS

Patient population
We retrospectively analyzed the medical records of patients who received anti-HCV therapy from September 2020 to June 2021 at our institution. The presence of ANA and the patient’s HCV viremia level were checked before initiating anti-HCV treatment. Patients who underwent a test of blood ANA with a positive test for HCV viremia were included. In this study, 258 patients with viremia were enrolled. The body mass index was measured for direct-acting antiviral agent therapy at the first visit. The comorbidities were recorded according to the medical record.

Method of ANA analysis
The ANA level was detected by the immunoassay of IIFA HEp-20-10 cells (EUROIMMUN, Luebeck, Germany) (Voigt et al., 2012). The serum samples were diluted with phosphate-buffered saline (PBS) starting from 1:10, 1:100, and 1:1000, and 30 µL of the diluted sample was drawn using a titer plate, overlaid onto a BIOCHIP slide, and incubated at room temperature for 30 min. The slides were washed with distilled water and soaked in PBS with Tween solution. Then, 25-µL anti-human globulin G labeled with fluorescein isothiocyanate was added, and the mixture was incubated at room temperature for 30 min. The slides were rewashed with distilled water and soaked in PBS with Tween solution for 5 min. All procedures were completed according to the manufacturers’ protocol by experienced technicians. Trained technicians read the slides using a fluorescence microscope (IF Sprinter, EUROIMMUN). Two medical laboratory scientists identified the ANA patterns and titer to reduce the bias. The patients were deemed ANA-positive if the titer values were >1:320. The titer of 1:320 was deemed to be strong fluorescence intensity at 1:10 dilution, moderate fluorescence intensity at 1:100 dilution, but negative fluorescence intensity at 1:1000 dilution. Every fluorescence pattern with titer values >1:320 was documented. The ANA patterns were differentiated according to the ICAP recommendations: Negative: AC-0; Nuclear pattern: AC-1 homogeneous, AC-2 dense fine speckled, AC-3 centromere, AC-4 fine speckled, AC-5 large/coarse speckled, AC-6 multiple nuclear dots, AC-7 few nuclear dots, AC-8 homogenous nucleolar, AC-9 clumpy nucleolar, AC-10 punctate nucleolar, AC-11 smooth nuclear envelop, AC-12 punctate nuclear envelope, AC-13 PCNA, AC-14 CENP-F, and AC-29 Topo-I; Cytoplasmic patterns: AC-15 fibrillar linear, AC-16 fibrillar filamentous, AC-17 fibrillar segmental, AC-18 discrete dots, AC-19 dense fine speckled, AC-20 fine speckled, AC-21 AMA, AC-22 Golgi, and AC-23 rods and rings; and mitotic patterns: AC-24 centrosome, AC-25 spindle fibers, AC-26 NuMA, AC-27 intercellular bridge, and AC-28 mitotic chromosomal (Chan et al., 2022).

Liver stiffness and steatosis measurements
The liver stiffness measurements and controlled attenuation parameter (CAP) were performed using FibroScan (Echosens), which showed accuracy in assessing steatosis and fibrosis with an area under the receiver operating characteristic curve values ranging from 0.70 to 0.89 (Eddowes et al., 2019). The following liver stiffness cutoff values were used for staging: F0 <6.5 kPa; F1 <8 kPa; F2 <9.5 kPa; F3 <12 kPa, and F4 ≥ 12 kPa (Wong et al.,
The diagnosis of non-alcoholic fatty liver disease was defined as the median value of CAP $\geq 248$ dB/m (Wong et al., 2010).

**Ethical considerations**

The Ethics Committee of Changhua Christian Hospital approved the study protocol used in this study (CCH IRB No: 220327), and the requirement for informed consent was waived because of the retrospective nature of this study.

**Statistical analysis**

Data are expressed as numbers with percentages, medians with interquartile ranges (Q1–Q3) (The first quartile Q1: 25th percentile, the third quartile Q3: 75th percentile), or means ± standard deviations. The Kolmogorov–Smirnov test was used to determine whether data have a normal or non-normal distribution. Student’s t-test or the Mann–Whitney U-test was used to compare continuous variables in the ANA(+) and ANA(−) groups. As appropriate, the frequencies of categorical variables were compared using the chi-square test or Fisher's exact test. Multivariate logistic regression analysis was performed to identify factors associated with ANA 1:640(+). Selected variables with $p$-values <0.10 from the crude mode (including age, sex (male), and estimated glomerular filtration rate (eGFR)) for the backward elimination procedure in the multivariate model. The results were considered statistically significant if the two-tailed $p$-value was <0.05 for all tests. Statistical analyses were performed using Statistical Package for the Social Sciences, version 22.0 (IBM Corp., Armonk, NY, USA).

**RESULTS**

**Clinical features of the study population**

Overall, 258 patients were enrolled for analysis. The characteristics of the patients are shown in Table 1. In the ANA(−) group, there were 184 patients, whereas, in the ANA(+) group, there were 74 patients. The mean age was 67.3 and 61.2 years in the ANA(+) and ANA(−) groups, respectively ($p = 0.001$). There was a female dominance in the ANA(+) group, accounting for 63.5% ($p = 0.023$). In the ANA(+) group, we found a lower HCV RNA viral load (5.72 log$_{10}$ IU/ML vs. 6.02 log$_{10}$ IU/ML; $p = 0.06$) and higher prevalence of advanced fibrosis (F3 and F4) (38.5% vs. 26.1%; $p = 0.098$).

**ANA pattern according to the ICAP**

The most detected ANA pattern was AC-1 ($n = 35$), accounting for 47.3%, followed by AC-4 ($n = 34$), accounting for 45.9%; AC-21 ($n = 13$), accounting for 13/74; AC-8 ($n = 12$), accounting for 17.6%; and AC-27 ($n = 10$), accounting for 16.2% (Table 2). More than one ANA pattern was detected in 36 patients in Table 3. The most mixed ANA pattern was AC-1 and AC-4 ($n = 7$), followed by AC-1, AC-4, and AC-21 ($n = 3$) and AC-1, AC-4, and AC-27 ($n = 3$).

**The clinical correlation with high ANA levels in patients with chronic HCV infection**

A high positive ANA level, with a titer value >1:640, was associated with older age, chronic kidney disease, and a significantly lower eGFR (77.76 vs. 87.94 mL/min/1.73 m$^2$; $p = 0.044$)
Table 1  Characteristics of the patients with positive results of ANA.

| Baseline characteristics                  | ANA 1:320 (+) | ANA(-) | P-value |
|-------------------------------------------|---------------|--------|---------|
| Case number                               | 74            | 184    |         |
| Age, years (Mean ± SD)                    | 67.3 ± 13.1   | 61.2 ± 12.9 | 0.001   |
| Gender male (n, %)                         | 27(36.5%)     | 96(52.2%) | 0.023   |
| Body Mass Index (Mean ± SD)               | 24.7 ± 3.7    | 24.7 ± 4.4 | 0.989   |
| Comorbidities                             |               |        |         |
| Hypertension (n, %)                        | 34(45.9%)     | 66(35.9%) | 0.133   |
| Diabetes mellitus (n, %)                   | 14(18.9%)     | 37(20.1%) | 0.828   |
| Chronic kidney disease (n, %)              | 6(8.1%)       | 9(4.9%)  | 0.378   |
| Cirrhosis                                  | 14(18.9%)     | 26(14.1%) | 0.336   |
| HCC (n, %)                                 | 4(5.4%)       | 5(2.7%)  | 0.283   |
| Malignancy (n, %)                          | 8(10.8%)      | 23(12.5%) | 0.706   |
| HCV RNA (log10 IU/ML) (Median(Q1-Q3))      | 5.72(4.44–6.39) | 6.02(5.01–6.52) | 0.060   |
| HCV Genotype (n, %)                        |               |        | 0.564   |
| 1                                         | 1(1.4%)       | 7(3.8%)  | 0.446   |
| 1a                                        | 4(5.4%)       | 15(8.2%) | 0.617   |
| 1b                                        | 39(52.7%)     | 72(39.1%) | 0.064   |
| 2(2,2a,2b)                                | 24(32.4%)     | 65(35.3%) | 0.766   |
| 3                                         | 2(2.7%)       | 6(3.3%)  | 1.000   |
| 6                                         | 1(1.4%)       | 7(3.8%)  | 0.446   |
| Mixed                                     | 0(0.0%)       | 1(0.5%)  | 1.000   |
| Unclassified                              | 3(4.1%)       | 11(6.0%) | 0.763   |
| Baseline ALT (U/L) (Median(Q1-Q3))        | 39.5(22–82)   | 44(27-91) | 0.574   |
| Baseline Bilirubin (mg/dL) (Median(Q1-Q3)) | 0.6(0.4–0.8) | 0.6(0.5–0.8) | 0.227   |
| Baseline eGFR (mL/min/1.73m2) (Median(Q1-Q3)) | 79.62(62.18–102.95) | 88.92(70.91–102.19) | 0.168   |
| Fibrosis (n, %)                            |               |        | 0.485   |
| F0                                        | 16(30.8%)     | 58(43.3%) | 0.162   |
| F1                                        | 7(13.5%)      | 18(13.4%) | 1.000   |
| F2                                        | 9(17.3%)      | 23(17.2%) | 1.000   |
| F3                                        | 8(15.4%)      | 13(9.7%)  | 0.400   |
| F4                                        | 12(23.1%)     | 22(16.4%) | 0.399   |
| F3 and F4 (n, %)                           | 20(38.5%)     | 35(26.1%) | 0.098   |

(Table 4). Multivariable analysis (Table 5) also showed the significance of the relationship between high positive ANA levels and lower eGFR (p = 0.008).

DISCUSSION

In our analysis, 28.7% of the patients with CHC were ANA-positive. According to the ICAP, the most detected ANA pattern was AC-1, followed by AC-4, AC-21, AC-8, and AC-27. Of the 74 ANA-positive patients, 36 had more than one ANA pattern. ANA-positive patients showed a lower HCV RNA viral load and higher prevalence of advanced fibrosis (F3 and
Table 2: The distribution of ANA pattern in chronic HCV patients according to international consensus on ANA pattern.

| ANA pattern                      | Number of positive/total positive samples (N = 74) | Percentage |
|----------------------------------|--------------------------------------------------|------------|
| Nuclear Homogeneous (AC1)        | 35/74                                            | 47.3%      |
| Nuclear dense fine speckled (AC2)| 0/74                                             | 0.0%       |
| Centromere (AC3)                 | 4/74                                             | 5.4%       |
| Nuclear fine speckled (AC4)      | 34/74                                            | 45.9%      |
| Nuclear large/coarse speckled (AC5)| 3/74                                      | 4.1%       |
| Multiple nuclear dots (AC6)      | 4/74                                             | 5.4%       |
| Few nuclear dots (AC7)           | 4/74                                             | 5.4%       |
| Homogeneous nucleolar (AC8)      | 12/74                                            | 16.2%      |
| Clumpy nucleolar (AC9)           | 2/74                                             | 2.7%       |
| Punctate nucleolar (AC10)        | 2/74                                             | 2.7%       |
| Smooth nuclear envelope (AC11)   | 1/74                                             | 1.4%       |
| Punctate nuclear envelope (AC12) | 0/74                                             | 0.0%       |
| PCNA-like (AC13)                 | 0/74                                             | 0.0%       |
| CENP-F-like (AC14)               | 0/74                                             | 0.0%       |
| Cytoplasmic fibrillar linear (AC15)| 0/74                                      | 0.0%       |
| Cytoplasmic fibrillar filamentous (AC16)| 2/74                                   | 2.7%       |
| Cytoplasmic fibrillar segmental (AC17)| 0/74                                  | 0.0%       |
| Cytoplasmic discrete dots/GW-body like (AC18)| 0/74                         | 0.0%       |
| Cytoplasmic dense fine speckled (AC19)| 0/74                                 | 0.0%       |
| Cytoplasmic fine speckled (AC20) | 0/74                                             | 0.0%       |
| Cytoplasmic reticular/AMA (AC21) | 13/74                                            | 17.6%      |
| Polar/Golgi-like (AC22)          | 0/74                                             | 0.0%       |
| Rods and rings (AC23)            | 2/74                                             | 2.7%       |
| Centrosome (AC24)                | 5/74                                             | 6.8%       |
| Spindle fiber (AC25)             | 0/74                                             | 0.0%       |
| NuMA-like (AC26)                 | 2/74                                             | 2.7%       |
| Intercellular bridge (AC27)      | 10/74                                            | 13.5%      |
| Mitotic chromosomal envelope (AC28)| 0/74                             | 0.0%       |
| Topo I-like (AC29)               | 0/74                                             | 0.0%       |

F4) without statistical significance. Higher positive ANA levels (>1:640) were significantly associated with a lower eGFR.

Patients with CHC are predisposed to have extrahepatic manifestations (Vergani & Mieli-Vergani, 2013). The most strongly associated disease is cryoglobulinemia (Giuggioli et al., 2017; Comarmond, Cacoub & Saadoun, 2020). Moreover, several systemic autoimmune diseases have also been reported, such as autoimmune thyroiditis (Jadali, 2013), glomerulonephritis (Negro et al., 2015), rheumatoid arthritis (Su et al., 2014), and SjS (Wang et al., 2014). The incidence of rheumatological manifestations in patients with CHC is estimated to be 38% (Priora et al., 2021). Besides, it has been noticed that several
Table 3  Mixed ANA pattern in patients with chronic HCV patient.

| ANA pattern (≥ 1:320) | Number/total positive samples (N = 74) | percentage |
|------------------------|----------------------------------------|-------------|
| AC 1 & AC 4            | 7/74                                   | 9.5%        |
| AC 1 & AC 4 & AC 21    | 3/74                                   | 4.1%        |
| AC 1 & AC 4 & AC 27    | 3/74                                   | 4.1%        |
| AC 1 & AC 4 & AC 24    | 2/74                                   | 2.7%        |
| AC 1 & AC 6            | 1/74                                   | 1.4%        |
| AC 1 & AC 8            | 1/74                                   | 1.4%        |
| AC 1 & AC 21           | 1/74                                   | 1.4%        |
| AC 4 & AC 5            | 1/74                                   | 1.4%        |
| AC 4 & AC 10           | 1/74                                   | 1.4%        |
| AC 4 & AC 24           | 1/74                                   | 1.4%        |
| AC 4 & AC 27           | 1/74                                   | 1.4%        |
| AC 5 & AC 27           | 1/74                                   | 1.4%        |
| AC 7 & AC 21           | 1/74                                   | 1.4%        |
| AC 8 & AC 9            | 1/74                                   | 1.4%        |
| AC 8 & AC 11           | 1/74                                   | 1.4%        |
| AC 26 & AC 27          | 1/74                                   | 1.4%        |
| AC 1 & AC 4 & AC 5     | 1/74                                   | 1.4%        |
| AC 4 & AC 8 & AC 21    | 1/74                                   | 1.4%        |
| AC 4 & AC 21 & AC 27   | 1/74                                   | 1.4%        |
| AC 1 & AC 4 & AC 7 & AC 27 | 1/74 | 1.4% |
| AC 1 & AC 4 & AC 8 & AC 23 | 1/74 | 1.4% |
| AC 1 & AC 4 & AC 10 & AC 21 | 1/74 | 1.4% |
| AC 1 & AC 4 & AC 24 & AC 27 | 1/74 | 1.4% |
| AC 4 & AC 6 & AC 7 & AC 8 | 1/74 | 1.4% |
| AC 1 & AC 4 & AC 6 & AC 7 & AC 8 & AC 21 | 1/74 | 1.4% |

Autoimmune diseases may be triggered during interferon therapy for patients with CHC (Pellicano et al., 2005; Wilson et al., 2002). Several studies have revealed that antithyroid autoantibodies and thyroid dysfunction may be triggered by IFN-alpha-based therapies for patients with CHC even without pre-existing thyroid abnormalities (Jadali, 2013; Marazuela et al., 1996). A nationwide population-based cohort study from Taiwan reported that the cumulative incidence of rheumatic diseases was lowest in HCV-uninfected cohorts (95% confidence interval (CI) [8.416%–10.734%]) compared with HCV-infected cohorts treated with (95% CI [12.417%–17.704%]) and untreated HCV-infected cohorts (95% CI [13.585%–16.479%]) (Cheng et al., 2021). This finding indicates that HCV infection was associated with some rheumatic diseases.

ANA is widely used for diagnosing several systemic autoimmune diseases, providing not only negative or positive results but also fluorescence patterns. In the past, we detected “antinuclear” antibodies and defined their patterns using immunoassay, including homogeneous, speckled, nucleolar, and nuclear rim (White & Robbins, 1987). IIFA Hep-2 allows the identification of autoantibodies targeted to antigens localized in the nucleus and
Table 4  Clinical feature with higher ANA level over than 1:640.

| Baseline characteristics | ANA 1:640 (+) | ANA(-) | P-value |
|--------------------------|--------------|--------|---------|
| Case number              | 24           | 234    |         |
| Age, years (Mean ± SD)   | 69.4 ± 11.8  | 62.3 ± 13.2 | 0.011   |
| Gender Male (n, %)       | 6(25.0%)     | 117(50.0%) | 0.020   |
| Body Mass Index (Mean ± SD) | 24.1 ± 4.1 | 24.8 ± 4.3 | 0.464   |
| Comorbidities            |              |        |         |
| Hypertension (n, %)      | 10(41.7%)    | 90(38.5%) | 0.759   |
| Diabetes mellitus (n, %) | 3(12.5%)     | 48(20.5%) | 0.431   |
| Chronic kidney disease (n, %) | 4(16.7%) | 11(4.7%) | 0.039   |
| Cirrhosis                | 4(16.7%)     | 36(15.4%) | 0.773   |
| HCC (n, %)               | 0(0.0%)      | 9(3.8%)  | 1.000   |
| Malignancy (n, %)        | 3(12.5%)     | 28(12.0%) | 1.000   |
| HCV RNA(log10 IU/ML)     | 5.7(5.19-6.34) | 5.95(4.89-6.46) | 0.573   |
| HCV Genotype (n, %)      |              |        | 0.713   |
| 1                        | 0(0.0%)      | 8(3.4%)  |         |
| 1a                       | 0(0.0%)      | 19(8.1%) |         |
| 1b                       | 14(58.3%)    | 97(41.5%) |         |
| 2(2,2a,2b)               | 9(37.5%)     | 80(34.2%) |         |
| 3                        | 0(0.0%)      | 8(3.4%)  |         |
| 6                        | 0(0.0%)      | 8(3.4%)  |         |
| Mixed                    | 0(0.0%)      | 1(0.4%)  |         |
| Unclassified             | 1(4.2%)      | 13(5.6%) |         |
| Baseline GPT (U/L) (Median(Q1-Q3)) | 34.5(16.5–72.5) | 44(27–92) | 0.098 |
| Baseline Bilirubin (mg/dL) (Median(Q1-Q3)) | 0.5(0.4–0.8) | 0.6(0.5–0.8) | 0.129 |
| Baseline eGFR (mL/min/1.73m2) (Median(Q1-Q3)) | 77.76(39.21–94.84) | 87.94(68.29–104.38) | 0.044 |
| Fibrosis (n, %)          |              |        | 0.652   |
| F0                       | 5(29.4%)     | 69(40.8%) |         |
| F1                       | 3(17.6%)     | 22(13.0%) |         |
| F2                       | 3(17.6%)     | 29(17.2%) |         |
| F3                       | 1(5.9%)      | 20(11.8%) |         |
| F4                       | 5(29.4%)     | 29(17.2%) |         |

cytoplasm and mitotic cells (Chan et al., 2016). The ICAP developed a classification tree for most staining patterns. There are homogeneous, speckled, dense, fine speckled, centromere, discrete nuclear dots, and nucleolar reported in nuclear patterns, and cytoplasmic patterns are fibrillar, speckled, reticular/mitochondrion-like, polar/Golgi-like, and rods and rings (Chan et al., 2022; Damoiseaux et al., 2019). These patterns were correlated with different rheumatological diseases and have been reported to play a significant role as an anti-marker of rheumatic pathology, particularly the AC-2 pattern (Pashnina et al., 2021).
Table 5  Multivariable analysis of factors associated with ANA1:640(+).

| Risk factor                  | crude OR    | P-value | Multivariate Adjusted OR | P-value |
|------------------------------|-------------|---------|--------------------------|---------|
| Age, yr                      | 1.05(1.01,1.08) | 0.013   | –                        | –       |
| Gender (Male)                | 0.33(0.13,0.87) | 0.025   | 0.31(0.12,0.82)          | 0.018   |
| BMI, kg/m²                   | 0.96(0.87,1.07) | 0.463   | –                        | –       |
| Hypertension                 | 1.14(0.49,2.68) | 0.759   | –                        | –       |
| Diabetes mellitus            | 0.55(0.16,1.93) | 0.354   | –                        | –       |
| Chronic kidney disease       | 4.05(1.18,13.91) | 0.026   | –                        | –       |
| Cirrhosis                    | 1.1(0.36,3.41)  | 0.869   | –                        | –       |
| HCC                          | –           | –       | –                        | –       |
| Malignancy                   | 1.05(0.29,3.75) | 0.939   | –                        | –       |
| HCV RNA (log10 IU/ML)        | 0.9(0.65,1.25)  | 0.531   | –                        | –       |
| Baseline GPT (U/L)           | 1(0.99,1)    | 0.320   | –                        | –       |
| Baseline Bilirubin (mg/dL)   | 0.5(0.11,2.35) | 0.383   | –                        | –       |
| Baseline eGFR (mL/min/1.73 m²)| 0.98(0.97,1) | 0.011   | 0.98(0.97,1)             | 0.008   |
| Fibrosis                     | –           | –       | –                        | –       |
| F0                           | 1           | 0.665   | –                        | –       |
| F1                           | 1.88(0.42,8.52) | 0.412   | –                        | –       |
| F2                           | 1.43(0.32,6.37) | 0.641   | –                        | –       |
| F3                           | 0.69(0.08,6.25) | 0.741   | –                        | –       |
| F4                           | 2.38(0.64,8.85) | 0.196   | –                        | –       |

Notes. Multivariate logistic regression analysis was performed to identify factors associated with ANA1:640(+). Selected variables with p-value < 0.10 from crude mode (including Age, Gender(Male), Baseline eGFR) for backward elimination procedure in the multivariable model.

There are several diseases; however, autoimmune diseases, such as hyperthyroidism, gastroparesis, and non-alcoholic fatty liver disease, were found to be associated with ANA positivity (Mitra & Ray, 2020; Parkman et al., 2022; Xun, 2021). Although the correlation remains unclear. A study from China on the relationship between ANA and various liver diseases showed that the incidence of ANA positivity in patients with hepatitis B virus (HBV) and HCV infection was 19.1% and 3.9%, respectively. The most common ANA patterns in patients with HBV infection were AC-1, AC-4, AC-21, AC-5, and AC-2. Nevertheless, the most common ANA patterns in patients with HCV were AC-21, AC-4, AC-1, and AC-5 (Wei et al., 2020). A recent study analyzed the prevalence and outcomes of autoantibodies in HCV-infected patients. The most common ANA patterns were homogeneous and speckled patterns, accounting for 43% and 36%, respectively, followed by nucleolar (7%), centromeric (7%), and rods and rings (7%) (Romano et al., 2022). Furthermore, another study revealed elevated serum markers of autoimmune hepatitis, namely, ANA, immunoglobulin G, smooth muscle actin, anti-LKM1, and soluble liver antigen, in patients with CHC (Simoes et al., 2019). However, the authors did not examine the association of these serum markers with the virological features of their patients with HCV infection or did not assess the association of these markers with different ANA patterns.
To the best of our knowledge, this is the first ANA analysis among patients with CHC with viremia according to the ICAP. Furthermore, this study provides insight onto HCV infection and autoimmunity.

In our analysis, the most detected pattern was AC-1, accounting for 25.9%, followed by AC-4, accounting for 25.2%; AC-21, accounting for 9.6%; and AC-8, accounting for 8.9%. In previous reports, the AC-1 pattern was associated with systemic lupus erythematosus, chronic autoimmune hepatitis, and juvenile idiopathic arthritis (Aringer et al., 2019; Petri et al., 2012). The AC-4 pattern is clinically indicated in systemic autoimmune rheumatic diseases, particularly SjS, lupus erythematosus, dermatomyositis, and systemic sclerosis (Aringer et al., 2019; Betteridge & McHugh, 2016; Shiboski et al., 2017; Trallero-Araguás et al., 2012). The AC-21 pattern was found in patients with primary biliary cholangitis and systemic sclerosis (Shuai et al., 2017; Zheng et al., 2017). Finally, the AC-8 pattern was found in patients with systemic sclerosis (Ceribelli et al., 2010; Mahler, Fritzler & Satoh, 2015). Our patient population has no clinical manifestations of the aforementioned rheumatological conditions. There is no prior research on ANA patterns in CHC with viremia, and we provide additional information regarding the new ANA pattern among patients with HCV infection. Thus, whether HCV per se causes the presence of such autoantibodies or triggers the subsequent development of the aforementioned rheumatological conditions requires further Investigation.

ANA positivity was mostly found in females, accounting for 63.5%. This finding is consistent with the findings of a study on the relationship between sex and autoimmune diseases, which reported that females are more likely to be ANA-positive than males (Whitacre, 2001). A study revealed that ANA-positive patients with CHC were significantly associated with higher levels of aspartate aminotransferase, alkaline phosphatase, and alpha-fetoprotein (Peng et al., 2001). Another study reported a faster rate of liver fibrosis in ANA-positive patients with CHC but without statistical significance (odds ratio = 1.8; p = 0.1452) (Yee et al., 2004). However, a recent study showed no correlation between cirrhosis, hepatic decompensation, HCC, and survival during the 10-year follow up in patients with CHC with or without autoantibody positivity (including ANA, ASMA, AMA, and anti-LKM (Gilman et al., 2018). Our data showed that the ANA(+) group had a lower HCV RNA viral load and higher prevalence of advanced fibrosis (F3 and F4). Additionally, in this study, we noticed higher ANA titers after adjusting for age and sex, which showed a significant association with a lower eGFR (p = 0.008). This study has some limitations. First, this is a retrospective study in a single institution involving a small sample. However, our study has one strength in evaluating hepatitis C viremic patients with their ANA profiles. Some patients had a positive or higher ANA titer with HCV viremia, as hepatitis C infection is associated with some autoimmune diseases. Knowing the baseline ANA profiles paves the way for further studies comparison of the evolution of ANA profile change following hepatitis C eradication. Second, there was no control group for comparison, and we didn’t have data on other autoantibodies, including ASMA, AMA, and anti-LKM1, in our cohort for further analysis. Third, we only analyzed the patients’ pretreatment data. A long-term follow-up study on patient outcomes, including fibrosis stage, hepatic decompensation,
cirrhosis, HCC, and other comorbidities, is required to assess ANA pattern changes after HCV eradication.

**CONCLUSIONS**

We found that the overall prevalence of ANA positivity in patients with CHC was 28.7%. The most detected ANA patterns were AC-1, AC-4, AC-8, and AC-21. ANA-positive patients revealed a lower HCV RNA viral load and a higher prevalence rate of advanced fibrosis, although there was no statistical significance. Furthermore, higher ANA titer values (>1:640) were significantly associated with a lower eGFR.

**ADDITIONAL INFORMATION AND DECLARATIONS**

**Funding**
This research was funded by the Changhua Christian Hospital (110-CCH-IRP-040). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Grant Disclosures**
The following grant information was disclosed by the authors:
The Changhua Christian Hospital: 110-CCH-IRP-040.

**Competing Interests**
The authors declare there are no competing interests.

**Author Contributions**
- Shun-Wen Hsiao conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.
- Chuan-San Fan performed the experiments, prepared figures and/or tables, and approved the final draft.
- Hsu-Heng Yen conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.
- Siou-Ping Huang analyzed the data, prepared figures and/or tables, and approved the final draft.
- Yang-Yuan Chen performed the experiments, authored or reviewed drafts of the article, and approved the final draft.
- Pei-Yuan Su conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.

**Human Ethics**
The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):
The Ethics Committee of Changhua Christian Hospital approved the study protocol used in this study (CCH IRB No: 220327).
Data Availability
The following information was supplied regarding data availability:

The raw data is available in the Supplemental Files.

Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.14200#supplemental-information.

REFERENCES

Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, Bossuyt X, Musset L, Cervera R, Plaza-Lopez A, Dias C, Sousa MJ, Radice A, Eriksson C, Hultgren O, Viander M, Khamashta M, Regenass S, Andrade LE, Wiik A, Tincani A, Rönnelid J, Bloch DB, Fritzler MJ, Chan EK, Garcia-De La Torre I, Konstantinov KN, Lahita R, Wilson M, Vainio O, Fabien N, Sínic RA, Meroni P, Shoenfeld Y. 2014. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Annals of the Rheumatic Diseases 73:17–23 DOI 10.1136/annrheumdis-2013-203863.

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández I, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR. 2019. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases 78:1151–1159 DOI 10.1136/annrheumdis-2018-214819.

Betteridge Z, McHugh N. 2016. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. Journal of Internal Medicine 280:8–23 DOI 10.1111/joim.12451.

Cacoub P, Saadoun D. 2021. Extrahepatic manifestations of chronic HCV infection. New England Journal of Medicine 384:1038–1052 DOI 10.1056/NEJMra2033539.

Cassani F, Cataleta M, Valentini P, Muratori P, Giostra F, Francesconi R, Muratori L, Lenzi M, Bianchi G, Zauli D, Bianchi FB. 1997. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 26:561–566 DOI 10.1002/hep.510260305.

Ceribelli A, Cavazzana I, Franceschini F, Airò P, Tincani A, Cattaneo R, Pauley BA, Chan EK, Satoh M. 2010. Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. Journal of Rheumatology 37:2071–2075 DOI 10.3899/jrheum.100316.
Chan EK, Damoiseaux J, Carballo OG, Conrad K, De Melo Cruvinel W, Francescantonio PL, Fritzler MJ, Garcia-De La Torre I, Herold M, Mimori T, Satoh M, von Mühlen CA, Andrade LE. 2015. Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 Cell patterns 2014-2015. *Frontiers in Immunology* 6:412 DOI 10.3389/fimmu.2015.00412.

Chan EK, Damoiseaux J, De Melo Cruvinel W, Carballo OG, Conrad K, Francescantonio PL, Fritzler MJ, Garcia-De La Torre I, Herold M, Mimori T, Satoh M, von Mühlen CA, Andrade LE. 2016. Report on the second International Consensus on ANA Pattern (ICAP) workshop in Dresden 2015. *Lupus* 25:797–804 DOI 10.1177/0961203316640920.

Chan EKL, von Mühlen CA, Fritzler MJ, Damoiseaux J, Infantino M, Klotz W, Satoh M, Musset L, García-De La Torre I, Carballo OG, Herold M, De Melo Cruvinel W, Mimori T, Andrade LEC, Committee I. 2022. The international consensus on ANA patterns (ICAP) in 2021-The 6th workshop and current perspectives. *The Journal of Applied Laboratory Medicine* 7:322–330 DOI 10.1093/jalm/jfab140.

Cheng JS, Lin YS, Hu JH, Chang MY, Ku HP, Chien RN, Chang ML. 2021. Impact of interferon-based therapy on Hepatitis C-Associated rheumatic diseases: a nationwide population-based cohort study. *Journal of Clinical Medicine* 10(4):817 DOI 10.3390/jcm10040817.

Chi CT, Chen CY, Su CW, Chen PY, Chu CJ, Lan KH, Lee IC, Hou MC, Huang YH. 2021. Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan. *Journal of Microbiology, Immunology and Infection* 54:385–395 DOI 10.1016/j.jmii.2019.09.006.

Choi C, Botros Y, Shah J, Xue P, Jones A, Galan M, Olivo R, Niazi M, Paterno F, Guerrera J, Pyrsopoulos NT. 2020. A case report of alloimmune hepatitis after direct-acting antiviral treatment in a liver transplant patient. *Journal of Clinical and Translational Hepatology* 8:459–462 DOI 10.14218/JCTH.2020.00062.

Comarmond C, Cacoub P, Saadoun D. 2020. Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals. *Therapeutic Advances in Gastroenterology* 13:1756284820942617 DOI 10.1177/1756284820942617.

Covini G, Carcamo WC, Bredi E, von Mühlen CA, Colombo M, Chan EK. 2012. Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C. *Antiviral Therapy* 17:805–811 DOI 10.3851/IMP1993.

Damoiseaux J, Andrade LEC, Carballo OG, Conrad K, Francescantonio PLC, Fritzler MJ, Garcia dela Torre I, Herold M, Klotz W, Cruvinel WM, Mimori T, von Muhlen C, Satoh M, Chan EK. 2019. Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. *Annals of the Rheumatic Diseases* 78:879–889 DOI 10.1136/annrheumdis-2018-214436.

Damoiseaux J, Andrade LE, Fritzler MJ, Shoenfeld Y. 2015. Autoantibodies 2015: from diagnostic biomarkers toward prediction, prognosis and prevention. *Autoimmunity Reviews* 14:555–563 DOI 10.1016/j.autrev.2015.01.017.
Eddowes PJ, Sasso M, Allison M, Tschantzis E, Anstee QM, Sheridan D, Guha IN, Cobbold JF, Deeks JJ, Paradis V, Bedossa P, Newsome PN. 2019. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 156:1717–1730 DOI 10.1053/j.gastro.2019.01.042.

Fianchi F, Ponziani FR, Pompili M. 2020. Primary biliary cholangitis development after hepatitis C virus eradication with direct acting antivirals: a case report and review of the literature. European Review for Medical and Pharmacological Sciences 24:1435–1439 DOI 10.26355/eurrev_202002_20202.

Gilman AJ, Le AK, Zhao C, Hoang J, Yasukawa LA, Weber SC, Vierling JM, Nguyen MH. 2018. Autoantibodies in chronic hepatitis C virus infection: impact on clinical outcomes and extrahepatic manifestations. BMJ Open Gastroenterology 5:e000203 DOI 10.1136/bmjgast-2018-000203.

Giuggioli D, Sebastiani M, Colaci M, Fallahi P, Gragnani L, Zignego AL, Antonelli A, Ferri C. 2017. Treatment of HCV-related mixed cryoglobulinemia. Current Drug Targets 18:794–802 DOI 10.2174/138945011666150825112105.

Jadali Z. 2013. Autoimmune thyroid disorders in hepatitis C virus infection: effect of interferon therapy. Indian Journal of Endocrinology and Metabolism 17:69–75 DOI 10.4103/2230-8210.107856.

Kajiyama Y, Kikuchi K, Takai A, Hosoya N, Hoshino H, Hino K, Miyakawa H. 2012. B-cell-activating factor affects the occurrence of thyroid autoimmunity in chronic hepatitis C patients treated with interferon alpha. Clinical and Developmental Immunology 2012:247973 DOI 10.1155/2012/247973.

Mahler M, Fritzler MJ, Satoh M. 2015. Autoantibodies to the mitochondrial RNA processing (MRP) complex also known as Th/To autoantigen. Autoimmunity Reviews 14:254–257 DOI 10.1016/j.autrev.2014.11.007.

Marazuela M, García-Buey L, González-Fernández B, García-Monzón C, Arranz A, Borque MJ, Moreno-Otero R. 1996. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clinical Endocrinology 44:635–642 DOI 10.1046/j.1365-2265.1996.751768.x.

Matsumoto K, Kikuchi K, Kajiyama Y, Takano Y, Mabuchi M, Doi S, Sato K, Miyakawa H, Yasuda I. 2018. Development of autoimmune hepatitis during direct-acting antiviral therapy for chronic Hepatitis C virus infection. Internal Medicine 57:2669–2673 DOI 10.2169/internalmedicine.0613-17.

Mitra A, Ray S. 2020. High-Titre ANA positivity in NAFLD: an uncommon presentation of a common disease. European Journal of Case Reports in Internal Medicine 7:001714 DOI 10.12890/2020_001714.

Montón C, Escudero MD, Pascual I. 2020. The development of type-1 autoimmune hepatitis after chronic hepatitis C (HCV) clearance by direct-acting antivirals (DAA). Revista Espanola de Enfermedades Digestivas 112:664–665 DOI 10.17235/reed.2020.6785/2019.
Negro F, Forton D, Craxì A, Sulkowski MS, Feld JJ, Manns MP. 2015. Extrahepatic morbidity and mortality of chronic hepatitis C. *Gastroenterology* 149:1345–1360 DOI 10.1053/j.gastro.2015.08.035.

Nguyen HH, Khathlan A, Fritzler MJ, Swain MG. 2018. A case series evaluating the impact of Hepatitis C eradication using direct acting antivirals on primary biliary cholangitis-associated autoimmunity. *BMC Gastroenterology* 18:97 DOI 10.1186/s12876-018-0826-7.

Novembrino C, Aghemo A, Ferraris Fusarini C, Maiavacca R, Matinato C, Lunghi G, Torresani E, Ronchi M, Garlaschi MC, Ramonetta M, Colombo M. 2014. Interferon-ribavirin therapy induces serum antibodies determining ‘rods and rings’ pattern in hepatitis C patients. *Journal of Viral Hepatitis* 21:944–949 DOI 10.1111/jvh.12281.

Parkman HP, Van Natta ML, Makol A, Grover M, McCallum RW, Malik Z, Koch KL, Sarosiek I, Kuo B, Shulman RJ, Farrugia G, Miriel L, Tonascia J, Hamilton F, Pasricha PJ, Abell TL, Consortium NGCR. 2022. Prevalence and clinical correlates of antinuclear antibody in patients with gastroparesis. *Neurogastroenterology & Motility* 34:e14270 DOI 10.1111/nmo.14270.

Pashnina IA, Krivolapova IM, Fedotkina TV, Ryabkova VA, Chersheneva MV, Churilov LP, Churilov VA. 2021. Antinuclear autoantibodies in health: autoimmunity is not a synonym of autoimmune disease. *Antibodies* 10(1):9 DOI 10.3390/antib10010009.

Pellicano R, Smedile A, Peyre S, Astegiano M, Saracco G, Bonardi R, Rizzetto M. 2005. Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist’s view. *Minerva Gastroenterologica E Dietologica* 51:55–61.

Peng YC, Hsieh SC, Yang DY, Tung CF, Hu WH, Huang WN, Chen GH. 2001. Expression and clinical significance of antinuclear antibody in hepatitis C virus infection. *Journal of Clinical Gastroenterology* 33:402–406 DOI 10.1097/00004836-200111000-00012.

Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sánchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Ilastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, Van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Centanaro Di Vittorio C, Degiovanni R, Peroni CL, Fusaro E. 2021. Autoantibodies and
rheumatologic manifestations in Hepatitis C Virus infection. Biology 10(11):1071 DOI 10.3390/biology10111071.

Romano C, Tortorella O, Dalla Mora L, Di Stasio D, Sellitto A, Adinolfi LE, Marrone A. 2022. Prevalence and outcome of serum autoantibodies in chronic Hepatitis C patients undergoing direct-acting antiviral treatment. Frontiers in Immunology 13:882064 DOI 10.3389/fimmu.2022.882064.

Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, Rasmussen A, Scofield H, Vitali C, Bowman SJ, Mariette X, Group ISsSCW. 2017. 2016 American College of Rheumatology/European league against rheumatism classification criteria for primary Sjögren’s Syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis & Rheumatology 69:35–45 DOI 10.1002/art.39859.

Shuai Z, Wang J, Badamagunta M, Choi J, Yang G, Zhang W, Kenny TP, Guggenheim K, Kurth MJ, Ansari AA, Voss J, Coppel RL, Invernizzi P, Leung PSC, Gershwin ME. 2017. The fingerprint of antimitochondrial antibodies and the etiology of primary biliary cholangitis. Hepatology 65:1670–1682 DOI 10.1002/hep.29059.

Simoes CC, Saldarriaga OA, Utay NS, Stueck AE, Merwat SK, Merwat SN, Schiano TD, Fiel MI, Stevenson HL. 2019. Direct-acting antiviral treatment of patients with Hepatitis C resolves serologic and histopathologic features of autoimmune hepatitis. Hepatology Communications 3:1113–1123 DOI 10.1002/hep4.1388.

Su FH, Wu CS, Sung FC, Chang SN, Su CT, Shieh YH, Yeh CC. 2014. Chronic hepatitis C virus infection is associated with the development of rheumatoid arthritis: a nationwide population-based study in taiwan. PLOS ONE 9:e113579 DOI 10.1371/journal.pone.0113579.

Trallero-Araguás E, Rodrigo-Pendás J, Selva-O’Callaghan A, Martínez-Gómez X, Bosch X, Labrador-Horrillo M, Grau-Junyent JM, Vilardell-Tarrés M. 2012. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis and Rheumatism 64:523–532 DOI 10.1002/art.33379.

Vergani D, Mieli-Vergani G. 2013. Autoimmune manifestations in viral hepatitis. Seminars in Immunopathology 35:73–85 DOI 10.1007/s00281-012-0328-6.

Voigt J, Krause C, Rohwäder E, Saschenbrecker S, Hahn M, Danckwardt M, Feirer C, Ens K, Fechner K, Barth E, Martinetz T, Stöcker W. 2012. Automated indirect immunofluorescence evaluation of antinuclear autoantibodies on HEP-2 cells. Clinical and Developmental Immunology 2012:651058 DOI 10.1155/2012/651058.

Wang Y, Dou H, Liu G, Yu L, Chen S, Min Y, Zhao K, Wang X, Hu C. 2014. Hepatitis C virus infection and the risk of Sjögren or sicca syndrome: a meta-analysis. Microbiology and Immunology 58:675–687 DOI 10.1111/1348-0421.12202.

Wei Q, Jiang Y, Xie J, Yang M, Zhang Y, Wu Z, Chen S, Liao Z, Lin Z, Gu J. 2020. Investigation and analysis of HEP 2 indirect immunofluorescence titers and patterns in various liver diseases. Clinical Rheumatology 39:2425–2432 DOI 10.1007/s10067-020-04950-7.
Whitacre CC. 2001. Sex differences in autoimmune disease. *Nature Immunology* 2:777–780 DOI 10.1038/ni0901-777.

White RH, Robbins DL. 1987. Clinical significance and interpretation of antinuclear antibodies. *Western Journal of Medicine* 147:210–213.

Wilson LE, Widman D, Dikman SH, Gorevic PD. 2002. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. *Seminars in Arthritis and Rheumatism* 32:163–173 DOI 10.1053/sarh.2002.37277.

Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, Choi PC, Kowo M, Chan AW, Merrouche W, Sung JJ, De Lédinghen V. 2010. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. *Hepatology* 51:454–462 DOI 10.1002/hep.23312.

Xun C. 2021. Distribution characteristics of ANA and ANCA in patients with hyperthyroidism. *Endocrine, Metabolic & Immune Disorders - Drug Targets* 21:1993–1997 DOI 10.2174/187153032099920111160420.

Yee LJ, Kelleher P, Goldin RD, Marshall S, Thomas HC, Alberti A, Chiaramonte M, Braconier JH, Hall AJ, Thursz MR. 2004. Antinuclear antibodies (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance. *Journal of Viral Hepatitis* 11:459–464 DOI 10.1111/j.1365-2893.2004.00530.x.

Yen HH, Su PY, Zeng YH, Liu IL, Huang SP, Hsu YC, Chen YY, Yang CW, Wu SS, Chou KC. 2020. Glecaprevir-pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting. *PLOS ONE* 15:e0237582 DOI 10.1371/journal.pone.0237582.

Zheng B, Vincent C, Fritzler MJ, Senécal JL, Koenig M, Joyal F. 2017. Prevalence of systemic sclerosis in primary biliary cholangitis using the new ACR/EULAR classification criteria. *Journal of Rheumatology* 44:33–39 DOI 10.3899/jrheum.160243.